Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 known ✓ | P05106 | 20/20 | 0.72 |
| ▸ | ITGA2B known ✓ | P08514 | 20/20 | 0.72 |
| ▸ | F2R | P25116 | 14/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL3495900 | 1.00 | ITGB3 (0.72) | ITGB3ITGA2BF2R | |
| Water SCHEMBL2787036 | 1.00 | ITGB3 (0.72) | ITGB3ITGA2BF2R | |
| Water SCHEMBL2877498 | 1.00 | ITGB3 (0.72) | ITGB3ITGA2BF2R | |
| SCHEMBL14427009 | 0.99 | ITGB3 (0.74) | ITGB3ITGA2BF2R | |
| SCHEMBL7738750 | 0.99 | ITGB3 (0.74) | ITGB3ITGA2BF2R | |
| SCHEMBL29427716 | 0.99 | ITGB3 (0.74) | ITGB3ITGA2BF2R | |
| SCHEMBL7815626 | 0.99 | ITGB3 (0.74) | ITGB3ITGA2BF2R | |
| SCHEMBL6937887 | 0.99 | ITGB3 (0.74) | ITGB3ITGA2BF2R | |
| SCHEMBL6935208 | 0.99 | ITGB3 (0.74) | ITGB3ITGA2BF2R | |
| Hydrochloric Acid SCHEMBL7500148 | 0.98 | ITGB3 (0.72) | ITGB3ITGA2BF2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279048-A1 | COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION | 2023-09-07 | — | — | US | disclosed |
| EP-3838293-A1 | COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF | Tissuetech, Inc. (US) | 2021-06-23 | — | — | EP | disclosed |
| EP-2872181-B1 | COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF | TISSUETECH INC (US) | 2020-11-18 | — | — | EP | disclosed |
| US-10253065-B2 | Compositions containing HC-HA/PTX3 complexes and methods of use thereof | TISSUETECH, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-10040821-B2 | Compositions containing HC-HA/PTX3 complexes and methods of use thereof | TISSUETECH, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-10041120-B2 | Predictive analysis for myocardial infarction | SCRIPPS HEALTH (US) | 2018-08-07 | — | — | US | disclosed |
| US-10029017-B2 | Pretargeted activatable cell penetrating peptide with intracellularly releasable prodrug | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-24 | — | — | US | disclosed |
| US-9808532-B2 | Peptides whose uptake in cells is controllable | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-11-07 | — | — | US | disclosed |
| US-20160376305-A1 | COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION | 2016-12-29 | — | — | US | disclosed |
| US-20160095931-A1 | COMPOSITIONS CONTAINING HC-HA COMPLEX AND METHODS OF USE THEREOF | TISSUETECH, INC. | 2016-04-07 | — | — | US | disclosed |
| US-9175066-B2 | Compositions containing HC-HA complex and methods of use thereof | TISSUETECH, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| EP-2421901-B1 | COMPOSITIONS CONTAINING HC HA COMPLEX AND METHODS OF USE THEREOF | TISSUE TECH INC (US) | 2015-10-28 | — | — | EP | disclosed |
| US-20150166624-A1 | COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF | TISSUETECH, INC. (US) | 2015-06-18 | — | — | US | disclosed |
| EP-2729802-B1 | METHOD OF ANALYZING CARDIOVASCULAR DISORDERS AND USES THEREOF | SCRIPPS HEALTH (US) | 2015-05-06 | — | — | EP | disclosed |
| US-20140005096-A1 | METHODS OF TREATING INFLAMMATION | CAROLUS THERAPEUTICS, INC. (US) | 2014-01-02 | — | — | US | disclosed |
| US-20130157347-A1 | Method of Analyzing Cardiovascular Disorders and Uses Thereof | VERIDEX, LLC (US) | 2013-06-20 | — | — | US | disclosed |
| US-20120134922-A1 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-31 | — | — | US | disclosed |
| WO-2010124296-A2 | COMPOSITIONS CONTAINING HC•HA COMPLEX AND METHODS OF USE THEREOF | TISSUETECH, INC. (US) | 2010-10-28 | — | — | WO | disclosed |
| US-20100183598-A1 | METHODS OF TREATING CARDIOVASCULAR DISORDERS | CAROLUS THERAPEUTICS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100093636-A1 | METHODS OF TREATING INFLAMMATION | CAROLUS THERAPEUTICS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10029017-B2 | Pretargeted activatable cell penetrating peptide with intracellularly releasable prodrug | DNPEP, FOLH1, CTSL | ITGB3 2853/4885ITGA2B 1634/4885F2R 1389/4885 |
| US-20100183598-A1 | METHODS OF TREATING CARDIOVASCULAR DISORDERS | TNNI3, TNNT2, FABP3 | ITGB3 2597/4885ITGA2B 2511/4885F2R 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.